Contraceptive News and Research

RSS

Public policy implications in abstinence-only programs

Study focused on young African American preteens in an urban area: This is a legitimate public health study and it did show that a certain type of abstinence only program can help some very young adolescents (average age 12) delay sexual initiation for up to 24 months.

3 Feb 2010

Medpage Today provides clinical perspective on most read medical stories

Which medical news stories are physicians reading to stay informed about key developments? MedPage Today publishes the Most Read Stories for the Past Week.

3 Feb 2010

Men welcome male contraceptive pill currently undergoing trials

Would you trust men to take a 'male pill'? That's the question posed to 380 people in North East England by a team from Teesside University which questioned people about the male contraceptive pill currently undergoing trials.

28 Jan 2010

Warner Chilcott receives complete response letter from FDA for low dose oral contraceptive

Warner Chilcott plc announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) to its New Drug Application submitted in March 2009 for its "low dose" oral contraceptive (also referred to as WC 3016).

27 Jan 2010

Reproductive coercion and partner violence increase risk of unintended pregnancy

Young women and teenage girls often face efforts by male partners to sabotage birth control or coerce pregnancy - including damaging condoms and destroying contraceptives - and these efforts, defined as "reproductive coercion," frequently are associated with physical or sexual violence, a study by a team of researchers led by UC Davis has found.

25 Jan 2010

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.

22 Jan 2010

Men who buy fake internet drugs for ED problems face significant health risks

Men who buy fake internet drugs for erection problems can face significant risks from potentially hazardous contents and bypassing healthcare systems could leave associated problems like diabetes and high blood pressure undiagnosed.

21 Jan 2010

Lupin's Mandideep facility receives FDA clearance

Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site. The company had received a Warning letter for its Mandideep site in May 2009. In the ensuing seven months, the company made significant enhancements and took appropriate corrective actions.

21 Jan 2010

Over 44% of internet Viagra is counterfeit

Research by UK, Swedish and American researchers shows that taking internet drugs can kill and bypassing health systems can leave life-threatening problems undiagnosed. It's estimated that 90% of counterfeit drugs are sold on the internet, 44% of internet Viagra is fake, the global sale of counterfeit drugs will reach $75 billion this year and EU seizures have risen dramatically. Counterfeit drug deaths include men who took fake erectile dysfunction drugs, pregnant women injected with fake iron for anaemia and children who took paracetamol syrup contaminated with antifreeze.

20 Jan 2010

UNAIDS chief calls for reduction in MTCT in Africa

UNAIDS Executive Director Michel Sidibe on Monday during a five-day trip in Kenya, called for a drastic reduction in mother-to-child transmission (MTCT) of HIV in sub-Saharan Africa, Capital News reports. "In our continent we still have 400,000 babies born every year with HIV and we know if we are capable of making sure that testing will become available universally to all our pregnant women, (and) that pregnant women also have access to treatment, we will prevent the transmission," Sidibe said (Karong'o, 1/11).

13 Jan 2010

Salt Lake City research center joins international drug trial program for painful menstrual cramps

A leading clinical research center in Salt Lake City has joined an international trial program to test an experimental new drug designed to treat painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and school.

12 Jan 2010

Researchers study VA111913 drug as a possible treatment for dysmenorrhea

A leading clinical research center in Austin has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

12 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

Obama administration supports Cairo conference goals, Clinton says

Secretary of State Hillary Rodham Clinton on Friday "reiterated the Obama administration's support" for universal access to family planning, improving maternal health care and other goals outlined at the 1995 International Conference on Population and Development Action Plan held in Cairo, Egypt, All Headline News reports.

12 Jan 2010

Health and development groups applaud Clinton speech; call for action

A broad coalition of organizations representing millions of Americans applauded today's statement by Secretary of State Hillary Clinton that the United States unequivocally supports the worldwide consensus that achieving universal access to reproductive health is critical for individual health, family well-being, broader economic development and a healthy planet.

9 Jan 2010

Watson Pharmaceuticals files ANDA with FDA seeking approval to market LoSeasonique

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its levonorgestrel and ethinyl estradiol (0.10 mg/0.02 mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by Duramed Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceutical Industries, Ltd.

9 Jan 2010

Discovery of inhibitory hormone may yield new treatments for cancer and other diseases

Nearly 10 years after the discovery that birds make a hormone that suppresses reproduction, University of California, Berkeley, neuroscientists have established that humans make it too, opening the door to development of a new class of contraceptive and possible treatments for cancer or other diseases.

23 Dec 2009

Women using DMPA experience high BMD loss, researchers say

Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.

22 Dec 2009

Gynaecological visits presents great opportunities for dialogue about sexual health

Visits to a gynaecologist or midwife are generally associated with different tests and/or prescriptions for contraceptives, but could offer so much more. Women, doctors and midwives are agreed that gynaecological visits presents great opportunities for dialogue about sexual health, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

16 Dec 2009

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes.

16 Dec 2009

Contraceptive News and Research

Public policy implications in abstinence-only programs

Medpage Today provides clinical perspective on most read medical stories

Men welcome male contraceptive pill currently undergoing trials

Warner Chilcott receives complete response letter from FDA for low dose oral contraceptive

Reproductive coercion and partner violence increase risk of unintended pregnancy

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

Men who buy fake internet drugs for ED problems face significant health risks

Lupin's Mandideep facility receives FDA clearance

Over 44% of internet Viagra is counterfeit

UNAIDS chief calls for reduction in MTCT in Africa

Salt Lake City research center joins international drug trial program for painful menstrual cramps

Researchers study VA111913 drug as a possible treatment for dysmenorrhea

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Obama administration supports Cairo conference goals, Clinton says

Health and development groups applaud Clinton speech; call for action

Watson Pharmaceuticals files ANDA with FDA seeking approval to market LoSeasonique

Discovery of inhibitory hormone may yield new treatments for cancer and other diseases

Women using DMPA experience high BMD loss, researchers say

Gynaecological visits presents great opportunities for dialogue about sexual health

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News